Tumor stiffness in breast cancer displays varied clinical implications depending on the tumor subtype, with higher stiffness indicating a more aggressive tumor biology particularly in hormone receptor-positive and HER2-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.